Search

Your search keyword '"de la Motte Rouge T"' showing total 27 results

Search Constraints

Start Over You searched for: Author "de la Motte Rouge T" Remove constraint Author: "de la Motte Rouge T" Publisher elsevier Remove constraint Publisher: elsevier
27 results on '"de la Motte Rouge T"'

Search Results

1. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.

2. Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé.

3. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.

4. MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.

5. Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study.

6. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

7. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.

8. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].

9. [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].

10. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

11. Cancer de l’ovaire : la rechute précoce.

12. [Fertility sparing treatment in women affected by cervical cancer larger than 2cm].

13. [Communication in the context of phase I clinical trials in oncology: implementation and evaluation of training programs].

14. [Targeted therapy in locally and metastatic recurrent cervical cancers].

15. [Management of enzalutamide, a new hormonal therapy].

16. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.

17. [Non oncologic applications of molecular targeted therapies].

18. [Ovarian yolk sac tumour: general review].

19. [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].

20. [New drugs in metastatic castration-resistant prostate cancer].

21. Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) Survey.

22. [New drugs and targeted therapeutic agents in ovarian cancer].

23. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

24. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.

25. [Medical treatment of metastatic or recurrent cancer of the cervix].

26. [Cannabis and cancer].

27. [Anemia in lymphoma].

Catalog

Books, media, physical & digital resources